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Abstract
 
The effect of infection history is ignored in most animal models of infectious disease. The at-
tachment protein of respiratory syncytial virus (RSV) induces T helper cell type 2–driven pul-
monary eosinophilia in mice similar to that seen in the failed infant vaccinations in the 1960s.
We show that previous influenza virus infection of mice: (a) protects against weight loss, illness,
and lung eosinophilia; (b) attenuates recruitment of inflammatory cells; and (c) reduces cyto-
kine secretion caused by RSV attachment protein without affecting RSV clearance. This pro-
tective effect can be transferred via influenza-immune splenocytes to naive mice and is long
lived. Previous immunity to lung infection clearly plays an important and underestimated role
in subsequent vaccination and infection. The data have important implications for the timing
of vaccinations in certain patient groups, and may contribute to variability in disease suscepti-
bility observed in humans.
Key words: viral immunology • murine model • eosinophils • major histocompatibility 
complex tetramers • mucosal immunology
 
Introduction
 
The maturation of the immune system may partly be deter-
mined by microbial exposure early in life (1, 2). The effect
of early childhood infections on subsequent development
of asthma and atopy has been widely discussed (3, 4). Early
exposure to mycobacteria (5), measles (6), and hepatitis A
(7) may decrease the incidence of Th2-driven diseases, and
the absence of gut flora leads to life-long inhibition of Th1
responses (8). Infants generally produce lower levels of
IFN-
 
g
 
, but this gradually increases with age (9). Collec-
tively, these findings have led to the formulation of the
“hygiene theory,” which suggests that reduced exposure to
microbes deprives us of essential immune-educational input
(10). Research into the effect of infection on immune re-
sponses to other antigens has mainly utilized agents such as
ovalbumin (for an example, see reference 11). However,
the effect of immunity to previous acute, successfully
cleared pathogens on other infectious diseases has received
little attention. We now use the murine model of respira-
tory syncytial virus (RSV)
 
1
 
 infection to address the impact
of sequential infections on immunopathology.
In the 1960s, vaccination of infants with formalin-inacti-
vated RSV resulted in a catastrophic enhancement of illness
during subsequent natural encounter with this virus, lead-
ing to eosinophilic lung infiltrates and excess mortality (12).
RSV is the most common cause of viral bronchiolitis in in-
fants and young children in the Western world (13), and
may also lead to asthma and atopy later in life (14). In
BALB/c mice, a primary infection induces mild illness and
a Th1 profile of immunity with resolution of infection in
7–10 d. Sensitization to the RSV attachment protein (G)
before RSV infection leads to enhanced illness, mimicking
that seen in the vaccine trials. Unlike a primary infection,
the G protein induces pulmonary eosinophilia, which de-
pends on CD4
 
1
 
 T cells producing type 2 cytokines (IL-4
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Abbreviations used in this paper: 
 
BAL, bronchoalveolar lavage; 
 
b
 
-gal, 
 
b
 
-galac-
tosidase; HA, hemagglutinin; LCMV, lymphocyte choriomeningitis vi-
rus; M2, second matrix protein; NP, nucleoprotein; QR, Quantum red;
RSV, respiratory syncytial virus.
 1318
 
Previous Infection History Improves RSV-induced Immunopathology
 
and IL-5 [15, 16]) but is inhibited by overexuberant CD8
 
1
 
T cells and IFN-
 
g
 
 (17). G-primed mice also display en-
hanced weight loss and illness (cachexia, ruffled fur, and re-
duced mobility) after RSV challenge.
The G-primed RSV infection model utilizes young in-
bred mice housed under strict pathogen-free conditions.
However, these conditions may not be applicable to real
life situations, as hosts are indeed exposed to numerous
pathogens that may influence the response to subsequent
infections. In the following study, we assess the influence
of previous exposure to influenza virus (which induces
strong IFN-
 
g
 
 responses from CD4
 
1
 
 and CD8
 
1
 
 T cells) on
the Th2-driven eosinophilia and illness seen in the G-primed
RSV mouse model. We demonstrate that such infection
history benefits the host and has profound, long-lasting in-
fluences on subsequent responses to an additional mucosal
infection. These findings have important implications for
the timing and nature of vaccinations.
 
Materials and Methods
 
Mice and Virus Stocks.
 
10–12-wk-old female BALB/c mice
(Harlan Olac Ltd.) were kept in pathogen-free conditions, ac-
cording to institutional and Home Office guidelines. RSV (A2
strain) and recombinant vaccinia virus (rVV) expressing the at-
tachment protein of RSV (rVV-G) or control 
 
b
 
-galactosidase
(rVV–
 
b
 
-gal) were grown in HEp-2 cells and assayed for infectiv-
ity (18). Influenza A X31 (hemagglutinin [HA] titer 1024) virus
was supplied by Prof. Alan Douglas (National Institute for Medi-
cal Research, London, UK). All stocks were free of mycoplasma
infection (determined by DNA hybridization; Gen-Probe Inc.).
 
Mouse Infection.
 
On day 0, mice were intranasally infected
with 3 
 
3
 
 10
 
6
 
 PFU of human RSV or 50 HA units of influenza
(in 50 
 
m
 
l) and left to recover for 3–5 wk. Mice were then scari-
fied on the rump with 3 
 
3
 
 10
 
6
 
 PFU rVV-G or rVV–
 
b
 
-gal (in 10
 
m
 
l). 14 d after vaccinia infection, mice were challenged intrana-
sally with 3 
 
3
 
 10
 
6
 
 PFU human RSV (in 50 
 
m
 
l). For brevity, the
sequence of viral infections has been simplified in the remainder
of the text. For example, intranasal RSV infection followed by
rVV-G scarification and then finally RSV infection is represented
by RSV–G-RSV (see Table I). The appearance and weight of
mice were monitored daily. Mice were killed 7 d after the final
viral infection by the injection of 3 mg pentobarbitone and ex-
sanguinated via the femoral vessels.
 
Illness Severity Score.
 
Mice were scored by an independent
observer using a standard grading system as follows: 0,
 
 
 
healthy; 1,
barely ruffled fur; 2, ruffled fur but active; 3, ruffled fur and inac-
tive; 4, ruffled fur, inactive and hunched; and 5, dead.
 
Cell Recovery.
 
Bronchoalveolar lavage (BAL), lung tissue, and
serum were harvested using methods described previously (19).
In brief, the lungs of each mouse were inflated six times with 1
ml of 12 mM lignocaine in Eagle’s minimum essential medium
and kept on ice. 100 
 
m
 
l of BAL fluid was cytocentrifuged onto
glass slides and stained with hematoxylin and eosin. The remain-
der of BAL fluid was centrifuged, the supernatant was retained
(stored at 
 
2
 
80
 
8
 
C), and the pellet was resuspended at 10
 
6
 
 cells/ml.
 
Production of MHC Class I Tetramer.
 
The gene encoding the
K
 
d
 
 allele was cloned from mouse splenocytes using PCR and
cloned into a T7 expression vector containing the biotin-[ace-
tyl-ConA-carboxylase]synthetase (BirA) substrate peptide (20).
Tagged K
 
d
 
 protein was purified using prokaryotic expression and
refolded with human 
 
b
 
2-microglobulin and peptide using stan-
dard methods (21). The peptides used were the immunodomi-
nant peptide TYQRTRALV from influenza nucleoprotein (NP)
or SYIGINNI from the second matrix protein (M2) of RSV.
The protein concentrate was biotinylated with BirA, and re-
folded monomers were purified using gel filtration and ion ex-
change before addition of streptavidin linked to PE. Tetramers
were tested for their ability to stain appropriate antigen-specific T
cell clones (data not shown) before use in experimental assays.
 
Flow Cytometric Analysis of Intracellular and Cell Surface Anti-
gens.
 
Cells were stained with Quantum red (QR)-conjugated
anti-CD8 or anti-CD4, FITC-conjugated CD45RB (both from
BD PharMingen), and PE-conjugated MHC H-2K
 
d
 
 tetramers for
30 min on ice. Samples were then fixed for 20 min at room tem-
perature with 2% formaldehyde. To detect intracellular cyto-
kines, 10
 
6
 
 cells/ml were incubated with 50 ng/ml PMA (Sigma-
Aldrich), 500 ng/ml ionomycin (Calbiochem), and 10 mg/ml
brefeldin A (Sigma-Aldrich) for 4 h at 37
 
8
 
C. Cells were then
stained for CD8-QR and/or PE-conjugated MHC tetramers as
described above and fixed. After permeabilizing with 0.5% sapo-
nin in PBS containing 1% BSA and 0.1% azide for 10 min,
FITC-conjugated anti–IFN-
 
g
 
 (XMG1.2; BD PharMingen) or
FITC-conjugated anti–IL-10 (JES 2A5; BD PharMingen) diluted
1:40 in saponin buffer was added. After 30 min, all samples were
washed with PBS containing 1% BSA and 0.1% sodium azide and
analyzed on a Coulter EPICS Elite flow cytometer collecting data
on at least 40,000 lymphocytes. Directly conjugated isotype-
matched control antibodies were used to set limits of background
fluorescence.
 
Enumeration of Eosinophils.
 
Eosinophils were enumerated as
granulocytes by flow cytometry, using their distinctive forward
and side scatter properties. Identification was confirmed by
counting eosinophils in hematoxylin and eosin–stained cytocen-
trifuge preparations.
 
Histology.
 
Mice were injected with 3 mg pentobarbitone and
exsanguinated. The trachea was exposed and 1 ml of 2% formalin
was instilled into the lungs. The inflated lungs were removed and
placed in tubes containing 5 ml of 2% formal saline. The next
day, samples were embedded in paraffin and sections were stained
with hematoxylin and eosin for histological analysis.
 
Lung Virus Titer.
 
Clearance of RSV was assessed in lung ho-
mogenates from four mice per group at days 2, 4, and 7 after
virus challenge. After centrifugation at 4,000 rpm for 4 min, su-
pernatant was titrated in doubling dilutions on HEp-2 cell mono-
layers. 24 h later, monolayers were washed and incubated with
peroxidase-conjugated goat anti-RSV antibody (Biogenesis). In-
fected cells were detected using 3-amino-9-ethylcarbazole
(AEC), with infectious units being enumerated by light micros-
copy.
 
Assessment of the Effect of Previous Infection on Vaccinia Virus Rep-
lication.
 
Mice were infected intranasally with influenza, RSV, or
HEp-2 antigen. After 3 wk, mice were then scarified on the
rump with rVV-G. On days 2, 4, and 7 after scarification, the in-
guinal lymph nodes (draining the site of scarification) and a 1-cm
square of scarified skin were removed. The inguinal lymph nodes
were homogenized through a 100-
 
m
 
m nylon cell strainer (Fal-
con; Becton Dickinson), and the cells were counted and then
surface stained for CD4-PE, CD8-QR, and CD45RB-FITC for
30 min on ice. After fixation in formaldehyde, expression of these
markers was assessed by flow cytometry.
Both the external and internal surfaces of the scarified skin
were scraped with a scalpel blade into serum-free medium, the
suspension was centrifuged at 500 rpm to remove large debris,
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and 200 
 
m
 
l was applied to a HEp-2 monolayer in 2-ml tissue cul-
ture wells in log
 
10
 
 dilutions from neat to 10
 
2
 
5
 
. After 2 h at 37
 
8
 
C,
an additional 1.8 ml of R10F was added and the cultures were in-
cubated for 24 h. The monolayers were then carefully washed
and two drops of Gentian Violet was added for 20 min. After
washing and drying, the number of virus plaques per well was
counted by light microscopy. This number was multiplied by the
dilution factor and then by five to adjust to plaques per milliliter
(as only 200 
 
m
 
l of virus was added initially). The average number
of plaques per milliliter for each dilution was then determined.
 
ELISA for RSV-specific Antibody.
 
ELISA coating antigen was
prepared by infecting HEp-2 cells with RSV strain A2 at 1 PFU/
cell. When significant sloughing of the monolayer was observed,
the infected cells were harvested, centrifuged, resuspended in 3
ml distilled water, and then subjected to 2 min of sonication (Ul-
trawave Ltd.). 50-
 
m
 
l aliquots were stored at 
 
2
 
20
 
8
 
C until re-
quired. Control antigen consisted of identically treated, unin-
fected HEP-2 cells. Microtiter plates were coated overnight at
37
 
8
 
C with 100 
 
m
 
l of a 1:100 dilution of either sonicated RSV or
HEp-2 cells. After blocking with 2% normal rabbit serum for 2 h,
dilutions of test samples (diluted in PBS containing 1% HEp-2 ly-
sate) were added for an additional 1 h at room temperature.
Bound antibody was detected using peroxidase-conjugated rabbit
anti–mouse Ig and 
 
O
 
-phenylenediamine (Sigma-Aldrich). Reac-
tions were stopped with 50 
 
m
 
l of 2.5 M sulfuric acid. Optical
densities were read at 490 nm (MR 5000; Dynatech Medical
Products). The optical densities from RSV-coated wells were
subtracted from those in HEp-2–coated wells for each sample.
 
Cytokine ELISA.
 
IL-4, IL-5, IFN-
 
g
 
, and TNF were assessed
in lung lavage supernatants by ELISA according to the manufac-
turers’ instructions (BD PharMingen/Becton Dickinson). In
brief, Immunosorb ELISA plates (Nunc) were coated with cap-
ture antibody and left overnight at 4
 
8
 
C. Wells were then washed
five times with PBS/0.05% Tween 20 and blocked with PBS/
10% fetal bovine serum for 1 h at room temperature. 100 
 
m
 
l of
sample (neat or diluted 1:2) or standard was added to blocked
wells for 2 h at room temperature. Bound cytokine was detected
using biotinylated anticytokine antibody, avidin horseradish per-
oxidase, and tetramethylbenzidine. Color development was
blocked with 2 N H
 
2
 
SO
 
4
 
, and optical densities were read at 450
nm. The concentration of cytokine in each sample was deter-
mined from the standard curve.
 
Purification of Influenza NP Tetramer–positive Cells.
 
10 mice
were infected intranasally with influenza and scarified with rVV-G
3 wk later. After an additional 5 wk, mice were infected intra-
nasally with RSV and 6 d later, lung and mediastinal lymph nodes
were removed, disrupted into a single cell suspension, and
counted. Individual nodes and lung were then incubated with bi-
 
otinylated influenza NP-containing MHC tetramers for 30 min
on ice. After washing, samples were incubated with avidin-
coated MACS microbeads (20 
 
m
 
l/10
 
7
 
 cells) and applied to a
cooled Minimax column (Miltenyi Biotec). Samples of flow-
through and column-bound cells were stained with QR-conju-
gated avidin (Sigma-Aldrich) and assessed for tetramer-positive
cells by flow cytometry. Less than 1% of flow-through, but
 
.
 
90% of column-bound cells stained with the influenza tet-
ramer.
 
CTL Assay.
 
Mice were infected with RSV or influenza, and
after 14 d, spleens were removed and disrupted through a nylon
mesh. Red blood cells were removed with ammonium chloride
and 2 
 
3
 
 10
 
7
 
 cells were added to a 25-cm
 
3
 
 flask in R10F contain-
ing 1% nonessential amino acids and 
 
b
 
2-mercaptoethanol. 5 
 
3
 
10
 
6
 
 of the remaining splenocytes were incubated with 1 PFU/ml
RSV or 1,000 HA influenza/10
 
7
 
 cells. After 2 h, these were
added to individual flasks containing splenocytes from either
RSV- or influenza-primed animals. After 5 d at 37
 
8
 
C, the cells
were counted and added as effectors in a chromium-release assay
containing 10
 
4
 
 RSV- or influenza-infected P815 cells (targets). In
one experiment, purified MHC tetramer–binding cells were used
directly ex vivo as effectors. Maximal and minimal lysis was deter-
mined by the addition of 2% Triton X-100 to targets or by incu-
bating targets without effectors, respectively. Plates were then
centrifuged at 800 rpm for 5 min and incubated at 37
 
8
 
C. After 4 h,
plates were recentrifuged and 50 
 
m
 
l of supernatant was analyzed in
a microplate scintillation counter (Top count; Packard).
 
Statistics.
 
Statistics were performed using a two-tailed analysis
of variance assuming unequal variance.
 
Results
 
Homologous and Heterologous Lung Infection Abrogates En-
hanced Illness in G-primed, RSV-challenged Mice.
 
In a stan-
dard experiment, mice are sensitized to the attachment G
protein of RSV by dermal scarification with a vaccinia vi-
rus construct. 2–3 wk later, these mice are intranasally chal-
lenged with whole RSV (this infection regime is denoted
by G-RSV). Mice treated in this way rapidly lose weight,
become cachexic, and develop lung eosinophilia. In the
following experiments, we determined what happens to
the illness and eosinophilia caused by G-RSV if those mice
had experienced a previous lung viral infection. The vari-
ous groups of mice and sequences of infection are summa-
rized in Table I. As RSV is grown and titered in HEp-2
cells, a lysate of these cells is used as a control for the first
 
Table I.
 
Schematic Diagram of the Infection Sequence in BALB/c Mice
 
Reference
group Main experimental groups Control groups
Designation HEp2–G-RSV RSV–G-RSV Flu–G-RSV HEp2–
 
b
 
-RSV RSV–
 
b
 
-RSV Flu–
 
b
 
-RSV
First infection: day 0 Control (HEp-2) RSV Influenza Control (HEp-2) RSV Influenza
Priming protein: day 21 G protein G protein G protein Control (
 
b
 
-gal) Control (
 
b
 
-gal) Control (
 
b
 
-gal)
Final infection: day 35 RSV RSV RSV RSV RSV RSV
Mice were intranasally infected with RSV, influenza, or HEp-2 lysate on day 0, and after 21 d scarified with rVV-G or rVV–
 
b
 
-gal. On
day 35, mice were infected intranasally with whole RSV and sacrificed 7 d later.
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infection. Mice infected with HEp-2 material alone consis-
tently show no weight loss or lung inflammation (data not
shown). Vaccinia virus–expressing 
 
b
 
-gal controls for the
vaccinia construct expressing the G protein. Therefore,
mice sequentially infected with HEp-2–
 
b
 
-gal–RSV effec-
tively experience a primary RSV infection and show mild
weight loss (typically 5–10%). Sequential infection of mice
with HEp-2–G-RSV represents a secondary infection to
the G protein leading to 15–20% weight loss (Fig. 1 A),
ruffled fur, and cachexia, similar to previous studies. These
two sequences of infection represent those to which others
are compared. Mice infected with RSV–
 
b
 
-gal–RSV (sec-
ondary infection to the whole virus) or with Flu–
 
b
 
-gal–
RSV display the same weight loss as a primary RSV in-
fection. Prior infection with RSV (RSV–G-RSV) and,
remarkably, with influenza virus (Flu–G-RSV), signifi-
cantly reduces G-induced weight loss (Fig. 1 A).
The beneficial effect of previous infection is also apparent
when illness severity is scored and by measuring lung eo-
sinophilia, which closely mirrors weight loss profile. All mice
are healthy on the day of the final infection (illness score of
0). A primary RSV infection induces minimal illness (illness
score of 
 
,
 
1; data not shown) and no eosinophilia. Mice
sensitized with rVV-G followed by RSV (HEp-2–G-RSV)
experience immediate illness at day 1 (which is prolonged
for 7 d after the final infection; Fig. 1 B) and extensive pul-
monary eosinophilia (Fig. 1 C). Eosinophilia is not due to
nonviral antigens (e.g., HEp-2 cells), as it is not induced in
the RSV–
 
b
 
-gal–RSV or the HEp-2–
 
b
 
-gal–RSV group.
Previous exposure to RSV or influenza (RSV–G-RSV or
Flu–G-RSV) significantly reduces the illness duration and
severity caused by the G protein. Both influenza- and
RSV-preprimed animals appeared completely healthy by
day 5 after the final RSV infection (Fig. 1 B). Previous in-
fection with RSV or influenza also abolishes G-induced
eosinophilia (Fig. 1 C). This dramatic effect of prior infec-
tion can be seen in hematoxylin and eosin–stained sections
of lung. Mice sequentially infected with HEp-2–G-RSV
have extensive lymphocytic and eosinophilic infiltrate sur-
Figure 1. Previous infection
prevents illness during second-
ary responses to the attachment
protein of RSV. (A) Weight loss
was monitored on the day of,
and during, the final RSV infec-
tion. The mean and standard de-
viation from five to six mice per
group are shown. (B) Illness was
monitored by a blinded observer
using a standard grading system
based on the degree of cachexia,
ruffled fur, and mobility. The re-
sults from five to six mice per
group per day were added (cu-
mulative disease severity score).
Mice experiencing secondary re-
sponses to the G protein are rep-
resented by the black bars; those
preinfected with RSV and influ-
enza are represented by the gray
and white bars, respectively. (C)
Eosinophils were enumerated in
hematoxylin and eosin–stained
cytocentrifuge preparations of
cells recovered by BAL. The re-
sults represent individual mice
from two independent experi-
ments. The groups are desig-
nated as follows: A, HEp-2–G-
RSV; B, HEp-2–b-gal–RSV; C,
RSV–b-gal–RSV; D, Flu–b-
gal–RSV; E, RSV–G-RSV; and
F, Flu–G-RSV.
Figure 2. Previous lung infection changes
the nature of the illness induced in rVV-G–
primed, RSV-challenged mice. Lungs were
inflated with 2% formalin in buffered saline,
removed, and embedded in paraffin. Repre-
sentative sections from HEp-2–G-RSV–
(right), RSV–G-RSV– (middle), and influ-
enza–G-RSV– (left) infected animals were
stained with hematoxylin and eosin. The
top panels show the extent of inflammatory
infiltrate in representative sections of lung
(original magnification: 3100); the bottom
panels show the presence of eosinophils (in-
dicated by arrows; original magnification:
31,000, oil immersion).
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rounding both blood vessels and airways (Fig. 2, right).
However, similar mice previously infected with RSV (Fig.
2, middle) or influenza (Fig. 2, left) have a different pattern
of illness where infiltrates are reduced, restricted to the
blood vessels, and contain no eosinophils.
Previous studies have shown that prior infection may al-
ter the replication of vaccinia virus (22), which may explain
the reduced eosinophilia and illness seen in our study. To
test this, mice were primed with HEp-2 antigen, RSV, or
influenza. After 3 wk, all mice were scarified with rVV-G
and at different time points the skin and draining inguinal
lymph nodes were removed. The titers of vaccinia recov-
ered from the skin lesions were identical at all time points
regardless of infection history (Fig. 3 A). There was also no
difference in the expansion (Fig. 3 B) and cellular com-
position (CD4 or CD8; data not shown) or activation
(CD45RB; Fig. 3 C) of cells in the draining inguinal lymph
nodes. In addition, administration of influenza virus after
the vaccinia virus has been cleared reduced eosinophilia,
weight loss, and illness, similar to mice infected with influ-
enza before rVV-G (data not shown). The results are also
not explained by residual inflammatory activity to, or im-
mune suppression by, the first infection. Mice had recov-
ered their original weight and displayed histology and BAL
cellular content similar to uninfected littermates. Prolifera-
tion assays to polyclonal stimulants or RSV showed no evi-
dence of immunosuppression regardless of infection history
(data not shown).
Previous Influenza Virus Infection Reduces Antibody to the
Attachment Protein (G) but Does Not Effect RSV Clearance.
RSV-specific antibody in serum was assessed by ELISA.
Mice undergoing a secondary infection to either whole
RSV (RSV–b-gal–RSV) or the G protein (HEp-2–G-
RSV) displayed enhanced antibody (endpoint titer of
1/1,024) compared with mice undergoing a primary infec-
tion to RSV (HEp-2–b-gal–RSV and Flu–b-gal–RSV;
endpoint of 1/32). Prior infection of G-primed, RSV-
challenged mice with RSV (RSV–G-RSV) enhanced anti-
body titers further (endpoint of 1/4,096). However, previ-
ous experience of influenza virus (Flu–G-RSV) lowered
antibody titers compared with G-primed, RSV-exposed
mice (endpoint of 1/128; data not shown).
G protein priming enhances the elimination of a subse-
quent RSV infection. Previous infection of these mice
with RSV or influenza did not alter RSV clearance as as-
sessed by plaque assay on lung homogenates. Despite lower
antibody titers in the Flu–G-RSV group, clearance of virus
from the lungs was unaffected. The recoverable RSV titer
on day 2 after the final infection was 4 6 1.3 3 105, 4.8 6
1.1 3 105, and 3.9 6 1.9 3 105 in HEp-2–G-RSV, Flu–
G-RSV, and RSV–G-RSV groups, respectively. No plaques
were recovered on day 4 after infection compared with
12.2 6 1.6 3 105 PFU/lung in mice undergoing a primary
RSV infection. All mice undergoing a secondary infection
to the G protein cleared virus by day 4 after the final intra-
nasal infection regardless of infection history. As observed
previously, all mice undergoing a primary RSV infection
showed a slower clearance of virus from the lungs (by day 7
after final infection).
Mechanisms for Reduction in Illness and Pathology. The G
protein does not induce CD81 T cells in BALB/c mice.
We (17) and others (23) have shown that CD81 T cells se-
creting IFN-g induced by other RSV proteins inhibit
G-primed lung eosinophilia. Therefore, we examined the
phenotype of CD81 T cells recruited to the lung by stain-
ing with H-2Kd tetramers containing the immunodomi-
nant epitopes from NP and RSV M2. Less than 0.5% in-
fluenza tetramer–positive cells were present in the lung
before RSV challenge and ,1% of these expressed IFN-g.
CD81 T cells from mice sequentially infected with RSV–
G-RSV do not bind the influenza NP MHC tetramer (Fig.
4 A) or an RSV M2–specific cell line (data not shown).
However, the M2-specific cell line does bind the MHC
class II M2–specific tetramer (Fig. 4 B). Sequential infec-
tion with Flu–G-RSV resulted in the recruitment of 16.9
6 2.7% of CD81 T cells that bound the influenza tetramer
(Fig. 4 C). 39.4 6 3.8% of these expressed IFN-g (Fig. 4
E) whereas, in a separate experiment, 49.6 6 6.4% were
CD45RBlow (data not shown). The observation that intra-
cellular IFN-g increases dramatically from 1% previously
to 39.4% after the final RSV challenge indicates activation
of influenza-specific CD81 T cells. In addition, influenza
tetramer–positive cells in the spleen and lung of Flu-
G–primed mice before RSV challenge were mostly
CD45RBhigh (data not shown). In Flu–G-RSV mice, 6.8 6
2.1% of CD81 T cells bound the RSV tetramer, which is
similar to mice undergoing a primary RSV infection
(HEp-2–b-gal–RSV; data not shown). In mice sequen-
tially infected with RSV–G-RSV, 13.8 6 1.7% of CD81
T cells bound the RSV tetramer (Fig. 4 D). Gating on
Figure 3. Previous lung infec-
tion does not alter the replica-
tion of rVV-G or the recruit-
ment of cells to the inguinal
lymph node. (A) Mice were in-
tranasally infected with HEp-2,
RSV, or influenza as shown and
scarified with rVV-G after 3 wk.
The number of plaques in the
scarified area of skin was assessed
after 24 h in HEp-2 monolayers.
(B) Inguinal lymph nodes were
also recovered and mechanically
disrupted. Total viable cell re-
covery on days 2, 4, and 7 is
shown. (C) The proportion of
CD45RBlow CD4 (left), and
CD8 (right) T cells was deter-
mined by flow cytometry from
HEp-2- (h), RSV- (n), and in-
fluenza- (e) preprimed mice.
The results represent the mean
and standard deviation of three
to four mice per group.
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these cells, we observed that 41.1 6 6.2% of RSV-specific
CD81 T cells expressed intracellular IFN-g (Fig. 4 F). Less
than 0.5% of CD81 T cells in these mice bound the influ-
enza tetramer. It is interesting to note that the intensity of
expression of tetramer varies between experiments. As T
cell receptor levels are sensitive to activation, we believe
this represents natural downregulation. The intensity of
IFN-g is also stronger in the RSV–G-RSV group (Fig. 4
F), which probably reflects activation by homologous
rather than heterologous antigen. Intracellular IL-10 was
also observed in MHC tetramer–stained cells (z10%), the
majority of which is present in cells that also produce IFN-g
(data not shown).
TNF and IL-4 were significantly reduced in the BAL
fluid (measured by ELISA) in Flu–G-RSV–infected mice.
RSV–G-RSV–infected mice also displayed reduced IL-4
and IL-5 in lavage supernatants, whereas TNF and IFN-g
remained unchanged compared with the HEp-2–G-RSV
group. The reduction in IL-4 and IL-5 may account for
the reduced eosinophil recruitment by previous infections
(Fig. 5).
Transfer of RSV- and Influenza-immune Splenocytes Partially
Protects Mice from G-induced Eosinophilia and Is Long Lived.
To determine whether protection from illness can be trans-
ferred, mice were primed with RSV or influenza and sple-
nocytes were recovered after 21 and 35 d. The cells were
then adoptively transferred into naive recipients, which
were then sensitized with rVV-G and challenged intrana-
sally with RSV 2 wk later. Weight loss, illness severity
score (data not shown), and lung eosinophilia (Fig. 6) were
improved in mice given either RSV- or influenza-immune
compared with naive splenocytes.
The protective effect of previous infection on G-induced
eosinophilia remains when the time between the first and
second infection is increased from 21 to 149 d. Eosino-
philia is significantly reduced in G-primed, RSV-chal-
lenged mice previously infected with influenza (Fig. 6,
shaded area). Remarkably, protection from weight loss and
illness severity was not maintained (data not shown). The
observed increase in CD81CD45RBlow cells in the BAL of
influenza-primed mice may account for the reduction in
eosinophilia (35.2 6 5.4% in HEp-2–G-RSV mice com-
pared with 50.2 6 9.7 in Flu–G-RSV mice, P , 0.01; data
not shown). Also, total intracellular IFN-g was raised by
previous influenza infection of rVV-G–primed RSV-chal-
lenged mice (20.66 6 2 compared with 12.48 6 4.73, P ,
0.01). The mechanisms associated with eosinophilia and ill-
ness therefore disassociate as the time between sequential
infections increases.
The effect of influenza infection on subsequent immu-
nity and pathology to RSV does not appear to be due to
Figure 4. RSV- and influenza-specific CD81 T cells are recruited back
to the lung during the final RSV infection. (A) BAL cells from mice se-
quentially primed with RSV–G-RSV do not bind the influenza NP–spe-
cific MHC tetramer. This sample was used to set the position of the
quadrant. (B) M2-specific cell lines bind the RSV M2–specific MHC tet-
ramer. The quadrant position was determined by staining the same sample
with the influenza NP–specific tetramer. This cell line was generated
from the spleen of rVV-M2–primed and RSV-challenged mice that had
been grown in vitro for 3 wk. (C and D) The presence of NP- and M2-
specific CD81 T cells in mice sequentially infected with Flu–G-RSV and
RSV–G-RSV, respectively. BAL was collected 7 d after the final RSV
infection and samples were stained with MHC tetramers and antibodies
to CD8. 40,000 lymphocytes were analyzed by flow cytometry. The
quadrant positions were determined from staining cells in the RSV–G-
RSV group with the NP-specific tetramer. (E and F) Anti-CD8– and tet-
ramer-stained cells were then permeabilized with saponin and stained
with FITC-conjugated antibody to IFN-g. The proportion of CD81, NP
(E), and M2 (F) tetramer–stained cells expressing IFN-g is shown. These
results are representative of four to five mice per group.
Figure 5. Previous infection
reduces Th2 cytokines during
secondary responses to the G
protein. Mice were infected with
HEp-2, RSV, or influenza, scari-
fied with rVV-G 21 d later, and
finally infected with RSV after
14 d. 7 d later, cytokine levels in
lavage fluid were examined by
ELISA and concentrations were
calculated using a standard curve
and linear regression analysis.
The mean and standard devia-
tion from individual mice in two
independent experiments are
shown.
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cross-reactive CD8 T cell epitopes. Splenocytes from influ-
enza- or RSV-infected mice were cultured with autolo-
gous APCs infected with RSV or influenza. After 5 d, cells
were used in a cytotoxicity assay with RSV- or influenza-
infected P815 cells. We were unable to test cytotoxic activ-
ity of influenza-immune splenocytes cultured with RSV, as
the majority of the cells died during the 5-d incubation pe-
riod, and those that were left did not stain with the influ-
enza-specific MHC tetramer. Similar cell death occurred
when RSV-immune splenocytes were cultured with influ-
enza virus. However, influenza-immune splenocytes cul-
tured with APCs infected with homologous virus ex-
panded rapidly. These cells only lysed targets infected with
influenza and not RSV (Fig. 7 A). To determine whether
cross-reactivity was occurring in vivo, influenza tetramer–
positive cells were purified using avidin-coated magnetic
beads from the lung and mediastinal lymph nodes of influ-
enza and rVV-G–infected mice 6 d after intranasal RSV
challenge. These cells were added directly to a cytotoxicity
assay containing RSV- and influenza-infected P815 cells
(Fig. 7 B). Although cells purified from 10 mice were
pooled, the maximum E/T ratios tested were 25:1. Re-
markably, at this E/T ratio significant lysis of influenza- but
not RSV-infected P815 cells was observed. Purified influ-
enza tetramer–positive cells were also assessed in triplicate
for proliferation to homologous or heterologous antigen.
Proliferative responses to RSV were not significantly above
the medium control (1,200 cpm with RSV compared with
1,384 cpm in medium alone, P . 0.09). This was not due
to a defect in the sorted cells, as extensive incorporation of
tritiated thymidine was observed in the presence of influ-
enza-infected APCs (16,098 6 1,034 cpm).
Discussion
The effect of exposure to one organism on the patho-
genesis of subsequent unrelated infections may have major
biological consequence. In this study, we demonstrate that
previous infection with influenza A virus dramatically pro-
tects mice from eosinophilia, weight loss, and illness caused
by the G protein of RSV. Although the reduction in eosin-
ophilia by influenza virus was variable, it was nonetheless
statistically significant in all experiments and may reflect
differences in the extent of the influenza-specific immune
response induced in individual animals. An important ob-
servation is that previous influenza virus infection reduces
G-induced eosinophilia for extended periods of time,
whereas the influence on weight loss and illness wanes.
This would indicate that the mechanisms for eosinophilia
and illness are distinct. The possible mechanisms for allevia-
tion of eosinophilia and illness include: (a) specific cross-
reactivity in RSV T and B cell epitopes by influenza-
primed cells; (b) bystander activation of influenza-specific
cells; (c) “immunological imprinting” (skewing towards a
Th1 phenotype); and (d) remodeling of the lung by the
first infection.
Cross-reactive Immunity. The beneficial effect of prior
RSV exposure (RSV–G-RSV) is mediated primarily by
specific recognition of epitopes within the homologous
challenge virus. Cross-reactive memory cytotoxic T cell
recognition of heterologous viruses has been described in
some studies (24, 25). Although individual CD41 and
CD81 T cells may react with up to one million peptides
(26), we have not observed cross-reactive immunity in
proliferation or cytotoxicity assays. Incubating influenza-
immune splenocytes with RSV in vitro for 5 d did not
expand a population of cells capable of proliferating to, or
lysing RSV-infected targets. Similarly, influenza tetramer–
positive cells did not lyse RSV-infected targets. However,
we cannot totally exclude cross-reactivity in vivo, as the
lung microenvironment and the virus-infected APCs may
support cross-reactivity. Prior RSV infection protects from
eosinophilia induced by formalin-inactivated RSV vaccina-
tion (27). We show that this protection can be transferred
and confers long-lasting strong protection. This may ex-
plain the absence of enhanced disease in older vaccinees
during the early human vaccine trials, as older children
Figure 6. Transfer of spleno-
cytes from RSV- and influenza-
immune mice partially protects
G-primed, RSV-challenged mice
from illness. Mice were intrana-
sally infected with RSV and in-
fluenza and left for 21–35 d. 3 3
107 spleen cells were then trans-
ferred intravenously into naive
animals. 1 d later, these mice
were scarified with rVV-G and
intranasally infected with RSV
after an additional 14 d. Eosino-
phils were assessed in lung lavage
samples in Giemsa-stained cytocentrifuge preparations. The shaded part
represents naive mice (j) or those infected with influenza (h), and left
for 149 d before G priming and RSV infection.
Figure 7. Splenocytes from
influenza-primed mice do not
kill RSV-infected targets.
Spleens from RSV- or influenza-
infected mice were removed af-
ter 14 d and disrupted to a single
cell suspension. After 5 d in the
presence of 2 PFU/cell of RSV
or 1 HA unit of influenza virus,
remaining cells were assessed for
cytotoxic activity. RSV-immune
mice effectively killed RSV-
infected targets (r). Influenza-
immune splenocytes similarly
killed influenza (m) but not
RSV-infected (j) targets. (B)
Influenza tetramer–positive cells
were purified from the lung and
mediastinal lymph nodes of 10
influenza-infected and RSV-
challenged mice using avidin-
coated magnetic beads and
MACS. A cytotoxicity assay
with influenza- (d) or RSV-
(e) infected P815 cells was then
performed. Spontaneous release has been subtracted from all results and
never exceeded 10% of maximal chromium release.
1324 Previous Infection History Improves RSV-induced Immunopathology
would presumably have been exposed to protective natural
lung infections before vaccination.
The effects described in this study are not explained by
increased RSV or vaccinia virus clearance. Selin et al. show
that prior immunity to lymphocyte choriomeningitis virus
(LCMV), Pichinde virus, and murine cytomegalovirus is
protective against a subsequent vaccinia virus infection
(22). We have not detected differences in vaccinia virus
replication in mice previously exposed to influenza or RSV
in our study, which may reflect the acute mild nature of
the infection and that replication is restricted to the lung.
In addition, in preliminary experiments, the variability in
the reduction of eosinophilia is identical when influenza vi-
rus is administered after the vaccinia virus.
G priming induces strong immunity with RSV clearance
4 d after infection. Although enhanced RSV-specific anti-
body occurred in all groups undergoing a secondary infec-
tion to either whole RSV or the G protein, viral clearance
still took 4 d. Influenza actually reduced RSV-specific anti-
body without changing viral clearance. It is possible that
recruited influenza-immune cells contribute to an environ-
ment in the lung that assists RSV clearance. CD81 T cells
can inhibit antibody production via production of IFN-g
(17, 28). The production of IFN-g by influenza-specific
CD81 T cells may therefore inhibit cytokines promoting B
cells, a hypothesis supported by the cytokine ELISA data.
Bystander Activation. The biological significance of by-
stander activation is hard to establish and should be treated
with caution. Cycling, cytolytically active CD81 T cells re-
main long after resolution of LCMV infection (29), provid-
ing a means for rapid elimination of subsequent infection
with homologous virus. This may also be true for activated
CD81 T cells specific for heterologous viruses. Using
MHC class I tetramers, we show that influenza NP–specific
CD81 T cells return to the lung and express intracellular
IFN-g and decreased CD45RB during RSV challenge. It is
interesting to note that the intensity of IFN-g expression is
lower in influenza-specific compared with RSV-specific
CD81 T cells responding to homologous antigen, which
may reflect differences in activation signals.
G protein–induced eosinophilia is sensitive to IFN-g
(17), and the return of influenza-specific CD81 T cells to
the lung may therefore tip the balance away from an envi-
ronment conducive to eosinophilia. As memory cells are
less dependent on costimulation compared with naive T
cells (30), express higher levels of adhesion molecules, and
are activated by IL-2, TNF, and IL-6 (31, 32), influenza-
specific T cells may experience bystander activation. By-
stander protection against heterologous virus has previously
been demonstrated but the biological consequence was
thought to be irrelevant (32–34). One problem with the
bystander theory is that if influenza-specific CD81 T cells
are undergoing bystander production of IFN-g, why do
memory T cells resident in non–influenza-primed mice also
not prevent eosinophilia? Memory responses to commensal
organisms and environmental antigens do not appear to
prevent G-induced eosinophilia. Influenza virus is particu-
larly powerful at expanding T cell memory responses with
Th1 cytokine profiles. Influenza-specific memory cells may
therefore prevent eosinophilia due to their recent activation
in the lung, their much increased frequency, and their pro-
duction of IFN-g but not Th2 cytokines.
Unlike the positive influence shown in the current
study, bystander activation has been linked to immunopa-
thology. Mice previously infected with LCMV show en-
hanced acute fatty necrosis after subsequent vaccinia virus
infection that may be mediated by excess IFN-g produc-
tion (22) and are more sensitive to bacterial LPS (35).
Coinfection of mice with Fasciola hepatica exacerbates dis-
ease to Bordetella pertussis (36), and Schistosoma mansoni egg–
induced granulomas cause vaccinia virus persistence (37).
Both viral and bacterial infections can interfere with pe-
ripheral tolerance (38), and bystander activation may in-
duce and maintain autoimmunity (39–41).
Immunological Imprinting and Lung Remodelling. Im-
mune responses in children are skewed to a Th2 phenotype
at birth and become more Th1-biased as they experience
subsequent infections (1). In our study, the IFN-g ob-
served by intracellular staining and the reduction in IL-4
protein in lavage fluid indicate a shift towards a Th1 phe-
notype. It should be noted that although intracellular IFN-g
was observed in influenza-specific CD81 T cells, IFN-g
protein in BAL supernatants was not significantly different
between groups. The effect on eosinophilia may therefore
represent a change in the ratio between Th1 and Th2 cy-
tokines, as IL-4 and IL-5 were decreased in influenza-
immune mice. IL-10 plays a major regulatory role in the
course of inflammatory responses by downregulating cell
recruitment and cytokine synthesis. The role of CD41 T
cells producing IL-10 and/or TGF-b has been extensively
examined in the gut (for example, see references 42–44).
Regulatory T cells producing IL-10 and/or TGF-b even
suppress immune responses to other antigens in the same
environment (45). TNF, on the other hand, has been
linked to illness and weight loss during infection with sev-
eral viruses (46). When released in large quantities, it enters
the bloodstream and is associated with weight loss and
wasting (47, 48). The reduction of TNF and the increase in
IL-10 in MHC tetramer–positive cells by previous infec-
tion may explain why illness is less severe than in naive G
protein–primed, RSV-challenged mice.
Decreased TNF-mediated lysis of antigen-activated or
virally infected cells (49, 50) may also explain the results of
this study. Such cell death in the large inflammatory infil-
trate, or the infected respiratory epithelium, may result in
the release of proinflammatory or damaging chemicals and
lead to the illness observed during RSV infection. Alterna-
tively, RSV-induced illness is thought to be a consequence
of the immune response rather than uncontrolled viral rep-
lication. A reduction in inflammatory infiltrate may explain
the reduced illness severity.
When influenza virus infection was given 149 d before
G protein priming, eosinophilia but not illness and weight
loss were abrogated. This divergence in different parame-
ters of illness is easily explained by the effect on cytokines
described above. The impact of previous influenza infec-
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tion on TNF levels may subside with time. On the other
hand, memory cells may still be recruited to the lung and
influence eosinophilia via the production of IFN-g. We
did observe enhanced recruitment of activated CD81 T
cells to the lung in influenza-primed mice. Finally, the ef-
fect of previous infection on lung remodelling warrants
further investigation. However, we did not observe an in-
crease in vasculature or other architectural changes in lung
tissue sections.
In summary, our results imply that infection history can
have a significant positive biological effect on the immuno-
pathology of subsequent unrelated infection. Clearly, vac-
cination against infectious diseases is a priority. However,
animals naive to previous infections may not be the correct
“role model” for infection-experienced humans. Further-
more, the composition of vaccines may need to be tailored
to each age group. Infants will have encountered fewer in-
fectious agents than adults, immunocompromised patients
may lose the “memory” of infection, and the elderly expe-
rience immune senescence. Interactions between unrelated
microorganisms have so far mostly been overlooked, but
they clearly need further research, both in laboratory-based
animal and in human studies.
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